Temozolomide

The addition of temozolomide to radiation therapy prolonged OS for patients with both co-deleted and non-co-deleted grade 2 gliomas, according to study results.

The addition of veliparib to adjuvant temozolomide failed to improve OS for patients with newly diagnosed, MGMT-hypermethylated glioblastoma, according to randomized phase 2/phase3 study results.

In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients with leiomyosarcoma and other soft tissue sarcomas, which was presented at the Connective Tissue Oncology Society Annual Meeting.

The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

The addition of interferon alfa to temozolomide significantly extended survival among patients with newly diagnosed high-grade gliomas, according to data published in JAMA Network Open.

The addition of an autologous tumor lysate-loaded dendritic vaccine to standard care extended OS among certain patients with glioblastoma, according to results of a prospective phase 3 trial published in JAMA Oncology.

CHICAGO — The addition of veliparib to adjuvant temozolomide did not extend OS or PFS among patients with newly diagnosed MGMT hypermethylated glioblastoma, according to results of a randomized phase 2/phase 3 trial presented at ASCO Annual Meeting.

Proper planning is essential for protecting assets in the event of divorce, according to attorney David B. Mandell, JD, MBA. His financial guide concerning divorce was the top story in hematology/oncology last week.

Morning administration of temozolomide appeared associated with longer OS compared with evening administration among patients with newly diagnosed glioblastoma, according to study results published in Neuro-Oncology Advances.

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma, according to a manufacturer-issued press release.